Payment overview · 2025
General Payments
$99.07
5 reported records · 5 companies
Healthcare provider profile · identity verified
Robert Lee Venable, M.D.
Allopathic & Osteopathic Physicians|General Practice · CRESWELL, NC · NPI 1750336855
Verified facts
What the public records show
CMS Open Payments records show Robert Lee Venable, M.D. received $99.07 in general payments during 2025 across 5 reported records.
Novo Nordisk Inc accounted for 24.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $24.55 | 24.8% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $21.66 | 21.9% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $20.17 | 20.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $19.20 | 19.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.49 | 13.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $99.07 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $24.55 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $24.55 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $21.66 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $20.17 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $19.20 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.49 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 64 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
40 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
64 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 335 | 94 |
| Amlodipine Besylate | Amlodipine Besylate | 324 | 86 |
| Omeprazole | Omeprazole | 253 | 70 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 237 | 68 |
| Lisinopril | Lisinopril | 202 | 52 |
| Potassium Chloride | Potassium Chloride | 201 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 201 | 47 |
| Gabapentin | Gabapentin | 197 | 44 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 187 | 34 |
| Alprazolam | Alprazolam | 175 | 29 |
| Losartan Potassium | Losartan Potassium | 175 | 47 |
| Levothyroxine Sodium | Levothyroxine Sodium | 170 | 47 |
| Furosemide | Furosemide | 146 | 35 |
| Pravastatin Sodium | Pravastatin Sodium | 146 | 39 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 144 | 38 |
| Allopurinol | Allopurinol | 125 | 36 |
| Ezetimibe | Ezetimibe | 123 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 122 | 34 |
| Eliquis | Apixaban | 121 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 119 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 114 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 100 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 97 | 30 |
| Simvastatin | Simvastatin | 96 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 89 | 25 |
| Tramadol Hcl | Tramadol Hcl | 87 | 29 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 85 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 81 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 80 | 24 |
| Metformin Hcl | Metformin Hcl | 74 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 72 | 22 |
| Fenofibrate | Fenofibrate | 71 | 14 |
| Metformin Hcl Er | Metformin Hcl | 71 | 25 |
| Ozempic | Semaglutide | 64 | 17 |
| Meloxicam | Meloxicam | 62 | 20 |
| Nifedipine Er | Nifedipine | 62 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 60 | 50 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 60 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 59 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 55 | 14 |
| Prednisone | Prednisone | 55 | 45 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 55 | suppressed |
| Atenolol | Atenolol | 50 | 14 |
| Clonazepam | Clonazepam | 49 | suppressed |
| Famotidine | Famotidine | 48 | suppressed |
| Jardiance | Empagliflozin | 47 | 13 |
| Carvedilol | Carvedilol | 46 | 12 |
| Naproxen | Naproxen | 46 | 17 |
| Glipizide | Glipizide | 45 | suppressed |
| Mounjaro | Tirzepatide | 44 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 43 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 42 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 41 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 40 | 13 |
| Meclizine Hcl | Meclizine Hcl | 40 | 11 |
| Trazodone Hcl | Trazodone Hcl | 40 | suppressed |
| Januvia | Sitagliptin Phosphate | 37 | 12 |
| Lorazepam | Lorazepam | 36 | suppressed |
| Finasteride | Finasteride | 35 | suppressed |
| Spironolactone | Spironolactone | 35 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 34 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 34 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 34 | suppressed |
| Glimepiride | Glimepiride | 33 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 33 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 33 | suppressed |
| Azithromycin | Azithromycin | 32 | 27 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 31 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 30 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 28 | suppressed |
| Celecoxib | Celecoxib | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 22 |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 24 | suppressed |
| Lansoprazole | Lansoprazole | 24 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | 11 |
| Sucralfate | Sucralfate | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Carisoprodol | Carisoprodol | 17 | suppressed |
| Cephalexin | Cephalexin | 17 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Fluconazole | Fluconazole | 16 | 11 |
| Invokana | Canagliflozin | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Amantadine | Amantadine Hcl | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Nexletol | Bempedoic Acid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $99.07 · 5 records | Novo Nordisk Inc | BREZTRI, Dexcom G6 Transmitter, OTEZLA, Ozempic, REPATHA, Rybelsus, Veozah | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error